Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02156804 | A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172) | completed | Phase 2 | 1,009 | Bristol-Myers SquibbINDUSTRY | 20 | Sep 11, 2020 | clinicaltrials |
| NCT03450876 | Long Term Quality of Life in Melanoma Patients in Netherlands | completed | — | 89 | Bristol-Myers SquibbINDUSTRY | 1 |
| Sep 11, 2020 |
| clinicaltrials |
| NCT02363283 | Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Aug 21, 2020 | clinicaltrials |
| NCT01512251 | BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma | completed | Phase 1 / Phase 2 | 8 | University of California, San FranciscoOTHER | 1 | Aug 17, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT01425008 | Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma | completed | Phase 1 | 149 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Aug 10, 2020 | clinicaltrials |
| NCT01886235 | Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery | completed | N/A | 10 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2020 | clinicaltrials |
| NCT00005617 | Vaccine Therapy in Treating Patients With Stage IV or Relapsed Malignant Melanoma | completed | Phase 1 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00039325 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma | completed | Phase 1 / Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00090896 | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery | completed | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01005472 | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | completed | Phase 1 | 16 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00498979 | Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers | completed | Phase 1 | 22 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01656642 | A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | completed | Phase 1 | 67 | Genentech, Inc.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT03253666 | Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component) | completed | — | 173,229 | Harvard School of Public Health (HSPH)OTHER | 0 | Jul 15, 2020 | clinicaltrials |
| NCT03415126 | A Study of ASN007 in Patients With Advanced Solid Tumors | completed | Phase 1 | 49 | Asana BioSciencesINDUSTRY | 1 | Jul 9, 2020 | clinicaltrials |
| NCT01211262 | Study to Assess the Tolerability of a Bispecific Targeted Biologic IMCgp100 in Malignant Melanoma | completed | Phase 1 | 84 | Immunocore LtdINDUSTRY | 2 | Jul 8, 2020 | clinicaltrials |
| NCT02823405 | X4P-001 and Pembrolizumab in Patients With Advanced Melanoma(X4P-001-MELA) | completed | Phase 1 | 16 | X4 PharmaceuticalsINDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT00339222 | Family Study of Melanoma in Italy | completed | — | 1,708 | National Cancer Institute (NCI)NIH | 2 | Jul 1, 2020 | clinicaltrials |
| NCT01773655 | Clinical and Histopathologic Characteristics of BAP1 Mutations | completed | — | 196 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT00341991 | Molecular Epidemiology of Cutaneous Malignant Melanoma | completed | — | 15,401 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2020 | clinicaltrials |
| NCT00112242 | Immunotherapy of Stage III/IV Melanoma Patients | completed | Phase 1 | 39 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | Jun 18, 2020 | clinicaltrials |
| NCT00889980 | Melanoma Molecular Profiling Analysis | completed | — | 237 | University of PittsburghOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT01866319 | Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | completed | Phase 3 | 834 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 2, 2020 | clinicaltrials |
| NCT01897116 | A Phase I Trial of Vemurafenib and Hydroxychloroquine in Patients With Advanced BRAF Mutant Melanoma | completed | Phase 1 | 8 | Abramson Cancer Center at Penn MedicineOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT00300612 | Vaccine Treatment for Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01682213 | Adjuvant Dabrafenib (GSK2118436) in Patients With Surgically Resected AJCC Stage IIIC Melanoma Characterized by a BRAFV600E/K Mutation | completed | Phase 2 | 23 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2020 | clinicaltrials |
| NCT02545075 | A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine | completed | Phase 3 | 182 | Bristol-Myers SquibbINDUSTRY | 1 | May 19, 2020 | clinicaltrials |
| NCT01704287 | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | completed | Phase 2 | 540 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 18, 2020 | clinicaltrials |
| NCT02223052 | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies | completed | Phase 1 | 89 | CelgeneINDUSTRY | 1 | May 12, 2020 | clinicaltrials |
| NCT02310503 | Spanish Registry of Mohs Surgery(REGESMOHS) | completed | — | 6,000 | Fundación Academia Española de DermatologíaOTHER | 1 | May 5, 2020 | clinicaltrials |
| NCT02516527 | A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors | completed | Phase 1 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | May 1, 2020 | clinicaltrials |
| NCT02431572 | A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy | completed | N/A | 11 | Massachusetts General HospitalOTHER | 1 | Apr 28, 2020 | clinicaltrials |
| NCT01916135 | PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative | completed | Phase 1 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2020 | clinicaltrials |
| NCT02285101 | Recombinant Human Arginase 1 (rhArg1) in Patients With Advanced Arginine Auxotrophic Solid Tumors | completed | Phase 1 | 23 | Bio-Cancer Treatment International LimitedINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT03002376 | An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1) | completed | Phase 1 | 47 | Regeneron PharmaceuticalsINDUSTRY | 4 | Apr 20, 2020 | clinicaltrials |
| NCT00597961 | Health Communication in Families | completed | — | 42 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 16, 2020 | clinicaltrials |
| NCT00342407 | The Incidence of Breast and Other Cancers Among Female Flight Attendants | completed | — | 6,093 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2020 | clinicaltrials |
| NCT00005971 | Flavopiridol in Treating Patients With Metastatic Malignant Melanoma | completed | Phase 2 | 17 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 9, 2020 | clinicaltrials |
| NCT01103635 | Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | completed | Phase 1 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02180061 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | completed | Phase 1 | 42 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 31, 2020 | clinicaltrials |
| NCT00118313 | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma | completed | Phase 1 | — | Craig L Slingluff, JrOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02354690 | Vemurafenib and TIL Therapy for Metastatic Melanoma | completed | Phase 1 / Phase 2 | 13 | Inge Marie SvaneOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT01363206 | Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma(GIPI) | completed | Phase 2 | 29 | Lynn E. Spitler, MDOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT01307267 | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | completed | Phase 1 | 190 | PfizerINDUSTRY | 5 | Mar 17, 2020 | clinicaltrials |
| NCT00062491 | Study of Karenitecin (BNP1350) to Treat Malignant Melanoma | completed | Phase 2 | 46 | BioNumerik Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01449279 | Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy | completed | Phase 2 | 22 | Stanford UniversityOTHER | 1 | Mar 2, 2020 | clinicaltrials |
| NCT01266603 | High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI | completed | Phase 2 | 44 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 19, 2020 | clinicaltrials |
| NCT01413191 | Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Feb 19, 2020 | clinicaltrials |
| NCT04274816 | Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma | completed | Phase 1 | 13 | A.J.M. van den EertweghOTHER | 0 | Feb 18, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Sep 11, 2020source: clinicaltrials